The Responder Lab provides AI‑driven analytical services for oncology drug development, using its Responder Atlas platform to model drug response from molecular structures and gene‑expression data. Their offerings include a Responder Architecture Certificate that predicts responder populations and sample‑size reductions for single compounds, a Responder Compass that prioritizes early‑stage candidates across up to 20 cancer types, and trial enrichment strategies that identify biomarkers and sub‑groups in Phase 2/3 studies.
Funding
Funding not disclosed
Founders
Product
Problem
Oncology drug development often suffers from limited predictive data for new compounds and difficulty identifying patient subgroups that will respond to a therapy, leading to costly trial failures and inefficient allocation of resources.
Solution
The Responder Lab applies a geometry-based AI platform to model oncology drug response using public gene‑expression and molecular data. For a single compound, the Responder Architecture Certificate imputes likely efficacy and biomarkers from the drug’s SMILES string and mechanism of action, without requiring sponsor data. The Responder Compass extends this analysis to prioritize early‑stage candidates across up to 20 cancer types, highlighting indications with the strongest projected response and associated responder populations. For ongoing Phase 2/3 trials, the Trial Enrichment Strategy leverages sponsor gene‑expression and outcome data to define responsive subgroups, validate biomarkers, and provide regulatory‑grade enrichment recommendations, enabling sample‑size reductions and more focused trial designs.
Target Audience
Primary customers are pharmaceutical and biotech companies developing oncology therapeutics, including pre‑clinical teams seeking compound prioritization and clinical development groups optimizing Phase 2/3 trial designs.
Features
- Geometry‑based response modeling that imputes efficacy from molecular structure (SMILES) and optional mechanism of action
- Predictive reports including responder population estimates, efficacy enrichment calculations, and sample‑size reduction guidance
- Multi‑cancer indication profiling for early‑stage compounds, covering up to 20 tumor types with projected response rates and biomarker enrichment
- Trial enrichment analysis using sponsor gene‑expression and outcome data to identify responsive subgroups and generate regulatory‑grade biomarker panels
- Out‑of‑sample validation of subgroup stability and biomarker relevance to support regulatory submissions
- Ability to analyze compounds lacking experimental data by leveraging structural similarity across the platform’s integrated datasets